The pure erythroleukemia: A case report and literature review

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 4, 2010, Pages 283-288

  Latif, Naeem ^a   Salazar, Elaine ^a   Khan, Rubina ^a   Villas, Bruce ^a   Rana, Fauzia ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CONTINUOUS INFUSION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ERYTHROBLAST; ERYTHROLEUKEMIA; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; LEUKEMIA REMISSION; MULTIPLE CYCLE TREATMENT; PAIN; PANCYTOPENIA; PURE ERYTHROLEUKEMIA; THORAX PAIN; THROMBOCYTE TRANSFUSION; TRISOMY 8; CHROMOSOME ABERRATION; DIFFERENTIAL DIAGNOSIS; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REVIEW;

CHROMOSOME ABERRATIONS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MIDDLE AGED; PROGNOSIS;

EID: 77954037434     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Di Guglielmo G. Le maltase eritremiche ed eritroleucemiche. II Pensiero Scientifico. Haematologica. 1928;9:301-347.
2. Roggli VL, Saleem A. Erythroleukemia: a study of 15 cases and literature review. Cancer. 1982;49:101-108.
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
4. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (IARC WHO Classification of Tumours). 4th ed. Lyon, France: WHO Press; 2008.
5. Goldberg SL, Noel P, Lumpp TR, Dewald G. The erythroid leukemias: a comparative study of erythroleukemia (FABM6) and Di Guglielmo disease. Am J Clin Oncol. 1998;21:42-47.
6. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk directed therapy in acute myeloid leukemia derived from the MRC AML10 trial. Br J Haematol. 1999;107: 69-79.
7. Davey FR, Abraham N, Brunetto VL, et al. Morphologic characteristics of erythroleukemia (acute myeloid leukemia; FAB-M6): a CALGB study. Am J Hematol. 1995;49:29-38.
8. Büchner T, Hiddemann W, Wörmann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML cooperative group. Blood. 1999;93:4116-4124.
9. Kowal-Vern A, Mazzella FM, Cotelingam JD, et al. Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases. Am J Hematol. 2000;65:5-13.
10. Olopade OI, Thangavelu M, Larson RA, et al. Clinical, morphologic and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood. 1992;80:2873-2882.
11. Mazzella F, Alvares C, Kowal-Vern A, Schumacher H. The acute erythroleukemias. Clin Lab Med. 2000;20:119-137.
12. Kowal-Vern A, Cotelingam J, Schumacher HR. The prognostic significance of proerythroblasts in acute erythroleukemia. Am J Clin Pathol. 1992;98:34-40.
13. Southcott MJ, Tanner MJ, Anstee DJ. The expression of human blood group antigens during erythropoiesis in a cell culture system. Blood. 1999;93:4425-4435.
14. Garand R, Duchayne E, Blanchard D, et al. Minimally differentiated erythroleukemia (AML M6 'variant'): a rare subset of AML distinct from AML M6. Groupe Francais d Hematologie Cellulaire. Br J Haematol. 1995;90:868-875.
15. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues (WHO Classification of Tumours). Lyon, France: IARC Press; 2001.
16. Atkinson J, Hrisinko MA, Weil SC. Erythroleukemia: a review of 15 cases meeting 1985 FAB criteria and survey of the literature. Blood Rev. 1992;6:204-214.
17. Park S, Picard F, Azgui Z, et al. Erythroleukemia: a comparison between the previous FAB approach and the WHO classification. Leuk Res. 2002;26:423-429.
18. Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long term study of 71 patients. Societe Francaise de Greffe de Moelle. Blood. 1996;88:358-365.
19. Ballen KK, Gilliland DG, Guinan EC, et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant. 1997;20:737-743.
20. Nakamura H. Cytogenetic heterogeneity in erythroleukemia defined as M6 by the French-American-British Cooperative Group criteria. Leukemia. 1989;3: 305-309.
21. Cuneo A, Van Orshoven A, Michaux JL, et al. Morphologic, immunologic and cytogenetics studies in erythroleukemia: evidence for a multilineage involvement and identification of two distinct cytogenetic-clinicopathological types. Br J Haematol. 1990;75:346-354.
22. Kottaridis PD, Gale RE, Frew ME, et al. The presence of FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752-1759.
23. Mazzella FM, Kowal-Vern A, Shirt A, Rector JT, Cotelingam JD, Schumacher HR. Effects of multidrug resistant gene expression in acute erythroleukemias. Mod Pathol. 2000;13:407-413.
24. Hugo F, Fernandez, Zhuoxin S, et al. Anthracycline Dose Intensification in Acute Myeloid Leukemia. N Engl J Med. 2009;361:2578.
25. Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008;111:1552-1559.
26. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1- ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107:1791-1799.